<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03776240</url>
  </required_header>
  <id_info>
    <org_study_id>TROIKA-1</org_study_id>
    <nct_id>NCT03776240</nct_id>
  </id_info>
  <brief_title>A Study to Demonstrate the Equivalent Pharmacokinetic Properties of a Single Intravenous Dose of HD201 and EU-Herceptin® and US-Herceptin® in Healthy Male Subjects</brief_title>
  <acronym>TROIKA-1</acronym>
  <official_title>A Phase I, Double-Blind, Randomised, Parallel Group Study to Demonstrate the Equivalent Pharmacokinetic Properties of a Single Intravenous Dose of HD201 and EU-Herceptin® and US-Herceptin® in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prestige Biopharma Pte Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prestige Biopharma Pte Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to demonstrate demonstrate the pharmacokinetic (PK) similarity of
      HD201 to the European (EU) and American (US) reference products Herceptin, following a single
      i.v. infusion of 6 mg/kg in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomised, parallel group study, where a total of 105 healthy adult
      male volunteers, ≥ 18 and ≤ 55 years of age, non-smoker, will be dosed; 35 subjects per
      treatment group, randomly assigned to one of the 3 treatment arms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Actual">August 19, 2019</completion_date>
  <primary_completion_date type="Actual">August 19, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under Curve (AUC, Pharmacokinetics)</measure>
    <time_frame>Up to day 54</time_frame>
    <description>Sampling will be performed in all patients to compare PK though values of HD201 and Herceptin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Incidence of anti-herceptin antibodies</measure>
    <time_frame>0 hour, Day 15, Day 29, Day 43, and Day 54 post-dose</time_frame>
    <description>Incidence of anti-herceptin antibodies</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>HD201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU-licensed Herceptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US-licensed Herceptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HD201</intervention_name>
    <description>Single-dose 6mg/kg body weight by 90 minute intravenous infusion</description>
    <arm_group_label>HD201</arm_group_label>
    <other_name>Trastuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EU-Herceptin</intervention_name>
    <description>Single-dose 6mg/kg body weight by 90 minute intravenous infusion</description>
    <arm_group_label>EU-licensed Herceptin</arm_group_label>
    <other_name>Trastuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>US-Herceptin</intervention_name>
    <description>Single-dose 6mg/kg body weight by 90 minute intravenous infusion</description>
    <arm_group_label>US-licensed Herceptin</arm_group_label>
    <other_name>Trastuzumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male, non-smoker (no use of tobacco products within 3 months prior to screening), ≥ 18
             and ≤ 55 years of age, with BMI &gt; 18.5 and &lt; 30.0 kg/m2 and body weight ≥ 50.0 kg.

          2. Healthy as defined by:

               1. the absence of clinically significant illness and surgery within 4 weeks prior to
                  dosing. Inclusion pre-dosing is at the discretion of the Principal Investigator.

               2. the absence of clinically significant history of neurological, endocrinal,
                  cardiovascular, pulmonary, hematological, immunologic, psychiatric,
                  gastrointestinal, renal, hepatic, and metabolic disease.

               3. a LVEF within the normal range as measured by echocardiogram (ECHO) within 4
                  weeks prior to randomization.

               4. the absence of clinically significant history of anaphylaxis, angioedema,
                  interstitial pneumonitis, or acute respiratory distress syndrome.

          3. Male subjects who are not vasectomized for at least 6 months, and who are sexually
             active with non-sterile female partner [sterile female partners include
             post-menopausal women (absence of menses for 12 months prior to drug administration)
             or women who have had a tubal ligation, hysterectomy, or bilateral oophorectomy (at
             least 6 months prior to drug administration)] must be willing to use one of the
             following acceptable contraceptive method throughout the study and for 90 days after
             the last study drug administration:

               1. simultaneous use of condom, and for the female partner hormonal contraceptives
                  (used since at least 4 weeks) or intra-uterine contraceptive device (placed since
                  at least 4 weeks);

               2. simultaneous use of male condom, and for the female partner, diaphragm with
                  intravaginally applied spermicide.

          4. Male subjects, including men who have had vasectomy, with a pregnant partner must
             agree to use a condom throughout the study and for 90 days after the last study drug
             administration.

          5. Male subjects must be willing not to donate sperm until 90 days following the last
             study drug administration.

          6. Capable of consent.

        Exclusion Criteria:

        f the following applies will be excluded from the study:

          1. Any clinically significant abnormality or abnormal laboratory test results found
             during medical screening or positive test for hepatitis B, hepatitis C, or HIV found
             during medical screening.

          2. Positive urine drug screen at screening.

          3. History of allergic reactions to trastuzumab, benzyl alcohol, murine proteins, or
             other related drugs.

          4. Any reason which, in the opinion of the Principal Investigator, would prevent the
             subject from participating in the study.

          5. Clinically significant ECG abnormalities (QTc &gt;450 ms) and or vital sign abnormalities
             (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure
             lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at
             screening.

          6. History of significant alcohol abuse within one year prior to screening or regular use
             of alcohol within six months prior to the screening visit (more than fourteen units of
             alcohol per week [1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]).

          7. History of significant drug abuse within one year prior to screening or use of soft
             drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs
             (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and
             amphetamine derivatives) within 1 year prior to screening.

          8. Previous use of trastuzumab or another monoclonal antibody for a medical condition or
             in the context of another clinical trial.

          9. Participation in a clinical research study involving the administration of an
             investigational or marketed drug or device within 30 days prior to the first dosing,
             administration of a biological product in the context of a clinical research study
             within 90 days prior to the first dosing, or concomitant participation in an
             investigational study involving no drug or device administration.

         10. Use of medication other than topical products without significant systemic absorption:

               1. prescription medication within 14 days prior to dose administration;

               2. over-the-counter products including natural health products (e.g. food
                  supplements and herbal supplements) within 7 days prior to dosing, with the
                  exception of the occasional use of acetaminophen (paracetamol - up to 2 g daily);

               3. a depot injection or an implant of any drug within 3 months prior to dose
                  administration.

         11. Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding
             volume drawn at screening) of 50 mL to 499 mL of blood within 30 days, or more than
             499 mL within 56 days prior to the first dosing.

         12. Hemoglobin &lt; 12.8 g/dL and hematocrit &lt; 0.37 L/L at screening.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa S Park</last_name>
    <role>Study Chair</role>
    <affiliation>Prestige Biopharma Pte Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Q Pharm</name>
      <address>
        <city>Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>December 13, 2018</study_first_submitted>
  <study_first_submitted_qc>December 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2018</study_first_posted>
  <last_update_submitted>August 27, 2019</last_update_submitted>
  <last_update_submitted_qc>August 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>randomized</keyword>
  <keyword>double-blind</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

